ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0420

Prospective Analysis of the Prevalence of Giant Cell Arteritis in Consecutive Newly Diagnosed Patients with Polymyalgia Rheumatica

Lara Burg1, Peter Brossart2, Charlotte Behning3 and Valentin Schaefer4, 1Clinic for Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 2Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 3Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 4Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany

Meeting: ACR Convergence 2020

Keywords: giant cell arteritis, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis affecting people aged 50 years and older.1 Although it is known, that GCA often coexists with polymyalgia rheumatica (PMR)2, to this point, the prevalence of GCA in consecutive newly diagnosed patients with PMR has not been investigated.

Methods: Consecutive patients with newly diagnosed PMR fulfilling the ACR /EULAR classification criteria3 were included. Vascular US examination of the extracranial arteries typically involved in GCA, such as axillary arteries, vertebral arteries, common carotid arteries, superficial temporal arteries with both frontal and parietal branches, occipital arteries, facial arteries and the central retinal arteries was performed in all PMR patients. Typical symptoms of GCA and PMR were recorded. Diagnosis of GCA was made, if intima-media thickness (IMT) was above respective cut-off values.4  

Results: Fifty patients with newly diagnosed PMR were included. In 27 PMR patients, GCA was diagnosed by vascular ultrasound (GCA-PMR group), while 23 PMR patients showed no evidence of GCA (PMR-group). Mean age of the PMR-GCA group was 74 years (SD ± 9) with ten (37%) females, while mean age in the PMR-GCA group was 71 years (SD ± 10.1) with seventeen (73%) females. Mean C-reactive protein (CRP) values were 29.4 mg/l (SD±24.5) in the PMR-group and 52.2 mg/l (SD±43.2) in the GCA-PMR group. CRP values were not found to be significant between groups (p = 0.1432). Forty-five of all patients (90%) described morning stiffness. Ten patients (37%) in the GCA-PMR group did not complain of any GCA symptoms, GCA was only detected by ultrasound examination. Every patient with diagnosis of PMR had shoulder or hip inflammation on US. Characteristic symptoms of PMR and GCA and the number of patients with respective symptoms are depicted in table 1 and 2.

Conclusion: Prevalence of GCA in patients with PMR in our cohort was 54%. CRP was higher in the GCA-PMR group compared to the PMR-group. Ten (37%) patients with GCA and PMR did not have any GCA symptoms. Performing vascular US in patients with PMR can be useful to diagnose a clinical inapparent GCA. Prompt onset of the respective therapy could prevent complications of GCA,  glucocorticoid therapy and probably improve disease outcome.

References

  1. Warrington KJ, Matteson EL. Management guidelines and outcome measures in giant cell arteritis (GCA). Clin Exp Rheumatol 2007;25:137–41.
  2. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. The Lancet 2008;372:234–45.
  3. Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012;64:943–54.
  4. Schäfer VS, Juche A, Ramiro S, Krause A, Schmidt WA. Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology (Oxford) 2017;56:1479–83.

Table 1. Number of patients fulfilling ACR/EULAR classification criteria for polymyalgia rheumatica


Disclosure: L. Burg, None; P. Brossart, None; C. Behning, None; V. Schaefer, None.

To cite this abstract in AMA style:

Burg L, Brossart P, Behning C, Schaefer V. Prospective Analysis of the Prevalence of Giant Cell Arteritis in Consecutive Newly Diagnosed Patients with Polymyalgia Rheumatica [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/prospective-analysis-of-the-prevalence-of-giant-cell-arteritis-in-consecutive-newly-diagnosed-patients-with-polymyalgia-rheumatica/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prospective-analysis-of-the-prevalence-of-giant-cell-arteritis-in-consecutive-newly-diagnosed-patients-with-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology